Role of RTEL1 in Microhomology-Mediated End Joining

RTEL1 在微同源介导的末端连接中的作用

基本信息

项目摘要

PROJECT SUMMARY/ABSTRACT Double-strand breaks (DSBs) can arise in DNA from exposure to radiation and pollutants prevalent in our environment. Inaccurate repair of DSBs can lead to genome rearrangements, which can cause intellectual disability, neurodegeneration, immunodeficiency, and cancer. DSBs are removed by two major pathways: nonhomologous end joining (NHEJ) and homologous recombination (HR), which are dependent on different factors and are mechanistically very distinct. Importantly, DNA breaks can also undergo microhomology- mediated end joining (MMEJ), in which limited homology in the ssDNA tails exposed by end resection triggers DNA strand annealing to initiate end joining repair. MMEJ leads to deletion of the DNA sequence situated between the regions of microhomology. As such, MMEJ is highly mutagenic, and is a hallmark of cancer cells. The discoveries that MMEJ possesses a dedicated DNA polymerase, POLq, and that it is employed frequently even when NHEJ and HR are intact support the premise that MMEJ is an evolutionarily conserved DSB repair pathway. Tumor cells deficient in NHEJ and HR rely heavily on MMEJ for viability upon treatment with chemotherapeutic DNA damaging agents. Inactivation of MMEJ would thus sensitize tumor cells to such treatments. A major goal of current MMEJ research is to identify novel factors that regulate or directly catalyze MMEJ, to define the genetic and biochemical underpinnings by which they function, and to test their value as potential druggable targets. We have identified RTEL1 as a novel factor that is required for efficient MMEJ. RTEL1 encodes an essential DEAH helicase that disassembles various DNA structures including a key recombination intermediate, the displacement loop (D-loop). We hypothesize that RTEL1 promotes MMEJ by dissociating D-loop structures that otherwise compete with MMEJ. Our model explains several enigmatic observations regarding the inhibitory roles of HR factors in MMEJ and provides a mechanistic framework for understanding the pathology of RTEL1-associated diseases. We will test this innovative idea using a combination of molecular genetics and in vitro biochemistry. This project will better define the mechanism of MMEJ and its regulation, and may reveal factors that can be targeted to treat environmentally induced diseases such as cancer and neurological disorders. As such, our work will exert a strong impact on environmental health research.
项目总结/文摘

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

JAMES MATTHEW DALEY其他文献

JAMES MATTHEW DALEY的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('JAMES MATTHEW DALEY', 18)}}的其他基金

The Role of Small RNAs in Homologous Recombination
小 RNA 在同源重组中的作用
  • 批准号:
    9167249
  • 财政年份:
    2016
  • 资助金额:
    $ 23.25万
  • 项目类别:
The Role of Small RNAs in Homologous Recombination
小 RNA 在同源重组中的作用
  • 批准号:
    9329413
  • 财政年份:
    2016
  • 资助金额:
    $ 23.25万
  • 项目类别:

相似海外基金

Novel Mechanisms of MED12-TGFbeta-mediated resistance to PARP Inhibitors in BRCA-deficient Cancer Cells
MED12-TGFbeta 介导的 BRCA 缺陷癌细胞对 PARP 抑制剂耐药的新机制
  • 批准号:
    10665588
  • 财政年份:
    2022
  • 资助金额:
    $ 23.25万
  • 项目类别:
Novel Mechanisms of MED12-TGFbeta-mediated resistance to PARP Inhibitors in BRCA-deficient Cancer Cells
MED12-TGFbeta 介导的 BRCA 缺陷癌细胞对 PARP 抑制剂耐药的新机制
  • 批准号:
    10536964
  • 财政年份:
    2022
  • 资助金额:
    $ 23.25万
  • 项目类别:
Carboplatin or Olaparib for BRcA deficient prostate cancer (COBRA)
卡铂或奥拉帕尼治疗 BRcA 缺陷型前列腺癌 (COBRA)
  • 批准号:
    10578711
  • 财政年份:
    2020
  • 资助金额:
    $ 23.25万
  • 项目类别:
Carboplatin or Olaparib for BRcA deficient prostate cancer (COBRA)
卡铂或奥拉帕尼治疗 BRcA 缺陷型前列腺癌 (COBRA)
  • 批准号:
    10417024
  • 财政年份:
    2020
  • 资助金额:
    $ 23.25万
  • 项目类别:
Metabolisms in BRCA-deficient and -proficient ovarian cancer as new therapeutic and diagnostic target.
BRCA 缺乏和丰富的卵巢癌的代谢作为新的治疗和诊断目标。
  • 批准号:
    18K09243
  • 财政年份:
    2018
  • 资助金额:
    $ 23.25万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Targeting BRCA Deficient Cells for Killing
针对 BRCA 缺陷细胞进行杀伤
  • 批准号:
    9114099
  • 财政年份:
    2015
  • 资助金额:
    $ 23.25万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了